Selecta Biosciences Secures $15.1M to Advance Immunobiology R&D
Firm’s platform uses nanotechnology to create targeted molecules.!--h2>
Selecta Biosciences received $15.1 million through a series B financing. The proceeds will be used to expand Selecta’s R&D activities in immunomodulatory nanoparticles and to advance the lead candidate through initial clinical evaluation.
Selecta’s product platform is being developed across broad areas of immunology from immune suppression, immune switching, to prophylactic and therapeutic vaccines, explains Aymeric Sallin, founder and managing director of NanoDimension, which was one of the investors. “This comes at a time of significantly increased business interests in immunomodulation, and Selecta’s technology, which is at the intersection of materials science and immunology, offers a robust and powerful platform for internal and partnered product development.”
Existing investors, Polaris Venture Partners and Flagship Ventures, were joined by NanoDimension and Timothy A. Springer, professor at Harvard Medical School Immune Disease Institute.